Modality
siRNA
MOA
CAR-T BCMA
Target
C5
Pathway
Apoptosis
SCLCSLE
Development Pipeline
Preclinical
Jul 2018
→ Feb 2030
PreclinicalCurrent
NCT07003022
994 pts·SCLC
2020-11→2030-02·Recruiting
NCT07562101
600 pts·SCLC
2018-07→2027-06·Not yet recruiting
1,594 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-06-121.2y awayInterim· SCLC
2030-02-033.8y awayInterim· SCLC
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Not yet…
Preclinical
Recruit…
Catalysts
Interim
2027-06-12 · 1.2y away
SCLC
Interim
2030-02-03 · 3.8y away
SCLC
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07003022 | Preclinical | SCLC | Recruiting | 994 | FEV1 |
| NCT07562101 | Preclinical | SCLC | Not yet recr... | 600 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Elratapinarof | Halozyme | Phase 2 | C5 |